JP2022534979A5 - - Google Patents

Info

Publication number
JP2022534979A5
JP2022534979A5 JP2021570866A JP2021570866A JP2022534979A5 JP 2022534979 A5 JP2022534979 A5 JP 2022534979A5 JP 2021570866 A JP2021570866 A JP 2021570866A JP 2021570866 A JP2021570866 A JP 2021570866A JP 2022534979 A5 JP2022534979 A5 JP 2022534979A5
Authority
JP
Japan
Prior art keywords
dioxopiperidine
carboxamide
isoindoline
oxo
trifluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534979A (ja
JP7496838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035043 external-priority patent/WO2020243379A1/en
Publication of JP2022534979A publication Critical patent/JP2022534979A/ja
Publication of JP2022534979A5 publication Critical patent/JP2022534979A5/ja
Priority to JP2024086242A priority Critical patent/JP2024123001A/ja
Application granted granted Critical
Publication of JP7496838B2 publication Critical patent/JP7496838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570866A 2019-05-31 2020-05-29 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法 Active JP7496838B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086242A JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
US62/855,619 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086242A Division JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Publications (3)

Publication Number Publication Date
JP2022534979A JP2022534979A (ja) 2022-08-04
JP2022534979A5 true JP2022534979A5 (enExample) 2023-05-30
JP7496838B2 JP7496838B2 (ja) 2024-06-07

Family

ID=73551319

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570866A Active JP7496838B2 (ja) 2019-05-31 2020-05-29 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法
JP2024086242A Pending JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086242A Pending JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Country Status (19)

Country Link
US (2) US11306101B2 (enExample)
EP (1) EP3976595B1 (enExample)
JP (2) JP7496838B2 (enExample)
KR (2) KR20250078628A (enExample)
CN (4) CN118724867A (enExample)
AR (1) AR119057A1 (enExample)
AU (1) AU2020282748A1 (enExample)
BR (1) BR112021022758A2 (enExample)
CA (1) CA3136753A1 (enExample)
CL (1) CL2021003134A1 (enExample)
CO (1) CO2021015624A2 (enExample)
IL (1) IL288278B2 (enExample)
MX (1) MX2021014350A (enExample)
MY (1) MY208545A (enExample)
PE (1) PE20220569A1 (enExample)
SG (1) SG11202112872YA (enExample)
TW (2) TW202523657A (enExample)
WO (1) WO2020243379A1 (enExample)
ZA (1) ZA202109003B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119057A1 (es) 2019-05-31 2021-11-17 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス， インコーポレイテッド Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション Ｎ－（（ｒ）－１－（３－クロロピリジン－２－イル）－２，２，２－トリフルオロエチル）－２－（（ｓ）－２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－カルボキサミドによる治療方法
AU2022289605B2 (en) * 2021-06-08 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
EP4540238A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Molecular glue degraders and methods of using the same
US20260055077A1 (en) * 2022-08-01 2026-02-26 Suzhou Kintor Pharmaceuticals, Inc. Protein degradation agent
CN120344512A (zh) * 2022-12-07 2025-07-18 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
US20260199316A1 (en) * 2022-12-07 2026-07-16 Hangzhou Glubio Pharmaceutical Co., Ltd Solid dispersion, preparation method therefor, and use thereof
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CA2822094C (en) * 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
CN101578277A (zh) * 2006-08-30 2009-11-11 细胞基因公司 5-取代的异二氢吲哚化合物
AU2007290407A1 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
AR119057A1 (es) 2019-05-31 2021-11-17 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos

Similar Documents

Publication Publication Date Title
JP2022520811A5 (enExample)
JP2021524484A5 (enExample)
JP2017525757A5 (enExample)
JP2022520448A5 (enExample)
JP2021529812A5 (enExample)
RU2373209C2 (ru) Пирролотриазиновые соединения как ингибиторы киназ
JP2023123854A5 (enExample)
TWI491603B (zh) 甲吡啶醯胺（ｐｉｃｏｌｉｎａｍｉｄｅ）與嘧啶－４－甲醯胺化合物、其製造方法及含其之醫藥組合物
JP2007519754A5 (enExample)
HRP20230201T1 (hr) Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste
JP2022043059A5 (enExample)
JP2015529224A5 (enExample)
IL276946B (en) Antiproliferative compounds and methods of use
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
JP2012503018A5 (enExample)
JP2005511745A5 (enExample)
JP2015531773A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
AU2009244082A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
JP2005529092A5 (enExample)
RU2012126987A (ru) Спироиндолциклопропаниндолиноны в качестве модуляторов амрк
JP2014527082A5 (enExample)
JP2019523266A5 (enExample)
RU2006100190A (ru) Производные хинолиламида в качестве антагонистов ccr-5
RU2018112993A (ru) Соединения и способы для ингибирования JAK
RU2015144385A (ru) Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы